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Abstract
Intravitreal antivascular endothelial growth factor drugs represent the current standard of care for neovascular
age-related macular degeneration (nAMD). Individualized treatment regimens aim at obtaining the same visual
benefits of monthly injections with a reduced number of injections and follow-up visits, and, consequently, of
treatment burden. The target of these strategies is to timely recognize lesion recurrence, even before visual
deterioration. Early detection of lesion activity is critical to ensure that clinical outcomes are not compromised
by inappropriate delays in treatment, but questions remain on how to effectively monitor the choroidal neo-
vascularization (CNV) activity. To assess the persistence/recurrence of lesion activity in patients undergoing
treatment for nAMD, an expert panel developed a decision algorithm based on the morphological features of
CNV. After evaluating all current retinal imaging techniques, the panel identified optical coherent tomography
as the most reliable tool to ascertain lesion activity when funduscopy is not obvious.
Keywords: neovascular age-related macular degeneration, choroidal neovascularization, lesion activity, mor-
phologic criteria, antivascular endothelial growth factor
Introduction
Neovascular age-related macular degeneration(nAMD) is a complex and progressive disease char-
acterized by choroidal neovascularization (CNV). The
prevalence of AMD, which is the most common cause of
irreversible blindness in Western Countries, is expected to
increase with the progressive aging of the population.1–4 In a
recent meta-analysis, Wong et al.5 estimated that the number
of people with AMD would rise to 196 million in 2020 and
to 288 million in 2040. AMD is a debilitating and far-
reaching condition, which leads to reduced quality of life
and higher rates of depression.6–8 Because AMD is a chronic
disease that requires life-long monitoring, its management
has become a major socioeconomic issue.9,10
Intravitreal antivascular endothelial growth factor (anti-
VEGF) drugs limit moderate and severe vision loss in most
nAMD patients and improve visual acuity (VA), thus re-
presenting the first-line treatment. The monthly regimen
used in the MARINA and ANCHOR trials showed clear
efficacy, despite the elevated treatment burden that such a
schedule would entail.11,12
To limit the economic and clinical load of this therapy,
physicians use a range of anti-VEGF dosing schemes for
nAMD. These include ‘‘pro-re-nata’’ (PRN; as needed),
whereby treatment is administered only when lesions are
classified as active, and the ‘‘treat-and-extend’’ (T&E)
schedule, where the interval between administrations is
gradually increased as the disease stabilizes, to maintain the
lesions quiescent with the fewest possible injections.13 An-
other regimen is the ‘‘observe-and-plan’’ (O&P), where the
key concept is to evaluate the individual need for retreatment
(after three loading doses), and then apply the optimal interval
in a fixed treatment plan of a series of injections.14 Moreover,
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the bimonthly regimen approved for aflibercept allows to re-
duce the number of injections at least during the first year.15
Individualized therapy, where each patient is managed
according to his/her disease characteristics, could potentially
lead to a reduction in the number of intravitreal injections and
patient visits, resulting in significant reduction of treatment
burden. Yet, the early detection of lesion activity is critical to
ensure that visual outcomes are maintained over time and not
compromised by inappropriate delays.
Randomized clinical trials define the reactivation of a
neovascular lesion based on specific morphological and
functional criteria (Table 1),16–20 although no unanimously
accepted definition of active lesion exists in clinical practice.
The best-corrected visual acuity (BCVA) is currently the only
globally accepted endpoint for clinical trials on AMD thera-
pies.21 However, even in advanced disease, BCVA can re-
main normal until the fovea is clearly affected. Most
choroidal neovascular membranes have been shown to arise
eccentrically and, therefore, initially have little effect on VA.2
Muether et al.22 compared the VEGF concentration be-
fore each injection of ranibizumab with optical coherent
tomography (OCT) and BCVA in AMD patients, and found
that the duration of VEGF suppression ranged between 26
and 49 days. OCT evidence of CNV activity was observed
after a mean of 93.7 days, while BCVA declined after a
mean of 114 days. These data concluded that OCT can
detect recurrence long before VA decline.22 Compared to
functional parameters (eg, VA), retinal imaging techniques
per se represent a sensitive and objective tool to detect signs
of lesion activity and, therefore, guide the decision as to
whether patients require further injections.22
The onset of a choroidal neovascular membrane can be
reliably recognized by clinical examination and conven-
tional imaging techniques. However, assessing the persis-
tence/recurrence of lesion activity may be more challenging,
as a long-standing disease determines structural changes of
neurosensory retina and surrounding tissues that could mask
the real progression of the disease.
The aim of this study was to perform a careful analysis of
the retinal imaging techniques currently available in clinical
practice, focusing on the morphological signs of persistence/
recurrence of CNV activity in patients undergoing anti-VEGF
Table 1. Representative Studies Using Tailored Regimens
Study
Treatment
protocol Criteria for lesion activity Instrumental follow-up
CATT (CATT
Research
Group et al.16)
PRN  Fluid on OCT
 New or persistent hemorrhage
 Decreased VA compared with
the previous examination
 Dye leakage or increased lesion
size on FA
 Monthly TD-OCT
 FA at the discretion of the
ophthalmologist
IVAN (IVAN Study
Investigators
et al.17)
PRN  Any SRF or increasing IRF on OCT
 Fresh blood
 VA loss of 10 letters
 Fluorescein leakage 25% of the lesion
circumference or expansion of CNV
 Monthly OCT
 Monthly fundus photo
 FA at the discretion of the
ophthalmologist
GEFAL
(Kodjikian et al.18)
PRN  Loss of five letters with no obvious
atrophy or subretinal fibrosis
and with fluid on OCT
 Active exudation on OCT (SRF unless
stable since the last 3 monthly injections,
macular edema with IRF, or increase in
CMT of at least 50 mm compared with
the previous examination)
 Increased CNV area or persistence
of leakage on FA
 New or persistent subretinal or intraretinal
macular hemorrhage
 Monthly TD/SD-OCT
 Monthly fundus photo
 FA or and/or ICGA at the
investigator’s discretion
(mandatory only at baseline
and 12 months)
HARBOR
(Busbee et al.19)
PRN  Five-letter decrease in VA from
the previous visit
 Any evidence of disease activity
on SD-OCT
 Monthly SD-OCT
 FA and fundus photography
at baseline and at months 3,
6, and 12
LUCAS
(Berg et al.20)
T&E  Any fluid on OCT
 New or persistent hemorrhage
 New or persistent dye leakage,
or increased lesion size on FA
 Monthly TD or SD-OCT
until there were no signs of
disease activity on OCT
and biomicroscopic fundus
examinations, then before
every scheduled injection
 FA allowed to aid in
retreatment decisions
CMT, central macular thickness; CNV, choroidal neovascularization; FA, fluorescein angiography; ICGA, indocyanine green
angiography; IRF, intraretinal fluid; OCT, optical coherence tomography; PRN, pro re nata; SD-OCT, spectral domain-OCT; SRF,
subretinal fluid; T&E, treat and extend; TD-OCT, time domain-OCT; VA, visual acuity.
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treatment. The information provided by each imaging tech-
nique was also compared, to simplify the diagnostic process
through the development of an image-based algorithm.
Methods
The Delphi method is a structured communication pro-
cedure designed for building consensus from experts in a
field through iterations of a survey and anonymous feed-
back.23 In this study, a modified Delphi technique was used,
which was based on a series of three consecutive face-to-
face meetings led by a moderator.
This study has been conducted by the members of an
Italian scientific society (Gruppo Angiografico Triveneto or
GAT) founded 30 years ago to promote the knowledge on
retinal diagnostics among ophthalmologists. The GAT study
group comprises eight experts coming from three universi-
ties and four hospitals. Although all members of the panel
are interested in retinal diseases, they hold different tasks in
their corresponding ophthalmologic institutions, which range
from retinal diagnostics to laser/pharmacological treatment
of retinal diseases and vitreoretinal surgery.
An English-language literature search using the PubMed
Library was initially performed, focusing on specific topics
inherent to the AMD, using the following keywords:
‘‘grading,’’ ‘‘histology,’’ ‘‘fluorescein angiography,’’ ‘‘in-
docyanine green angiography,’’ ‘‘spectral domain OCT,’’
‘‘OCT angiography,’’ and ‘‘anti-VEGF.’’ This was followed
by a manual search of references cited in selected articles
published in peer-reviewed journals.
Each member was assigned a specific topic that was pre-
sented to the entire group during the first meeting. During the
second round, the participants presented a collection of clin-
ical cases, questioning about advantages and disadvantages of
each retinal imaging technique in the clinical decision-making
process. During the third conference, the moderator proposed
an anonymous survey made up of multiple-choice questions
to identify key elements for the discussion, focusing on the
assessment of response to anti-VEGF and the sensitivity and
specificity of each imaging technique. The hypothesis cata-
logue that was used to guide the debate is shown in Supple-
mentary Table S1 (Supplementary materials are available
online at www.liebertpub.com/jop). The results of the debate
were summarized in a treatment algorithm and approved
unanimously by all members of the working group.
This article does not include original data from clinical
trials conducted by any of the authors.
Results
The imaging tools currently used for the diagnosis and
follow-up of nAMD patients comprise color fundus photog-
raphy (CFP), fluorescein angiography (FA) and indocyanine
green angiography (ICGA), and OCT and OCT angiography
(OCT-A).
Color fundus photography
CFP is the closest imaging modality to correlate with
clinical ophthalmoscopy and, until recently, was the gold
standard for grading and staging in AMD clinical trials.24,25
At the time of nAMD diagnosis, the CFP features indicating
the presence of a CNV are as follows: serous detachment
of the sensory retina, hemorrhage, retinal pigment epithe-
lial detachment (non-drusenoid type), fibrous tissue, or hard
exudates.26 Amoaku et al.27 consider evidence of disease
activity as the presence of significant new hemorrhage or
exudates. However, when monitoring patients undergoing
anti-VEGF treatment, only the appearance of a new retinal
or subretinal hemorrhage is a reliable marker of disease
activity. Indeed, the presence of hard exudates is a secondary
phenomenon occurring when the extracellular fluid that ac-
cumulates within the retina is reabsorbed into the retinal
capillaries.28
Fluorescein angiography
CNV typically leaks on FA. The FA leakage patterns of
CNV are classified as classic or occult and correlate gener-
ally with the anatomic classification, with occult membranes
analogous to type 1 CNV (located beneath the pigment epi-
thelium) and classic membranes similar to type 2 CNV (lo-
cated in the subretinal space).29 The histopathological features
determining the angiographic behavior of CNV are the vessel
caliber (larger for type 2 CNV, which increases the amount of
leakage) and the consistency of surrounding fibrocellular
tissue (thicker in type 1 CNV, which obscures the neovascular
lesion).30,31
Besides these two subtypes of CNV, retinal angiomatous
proliferation (RAP; type 3 CNV) and idiopathic polypoidal
choroidal vasculopathy (IPCV) have been recognized as
peculiar forms of nAMD.
RAP refers to the development of new vessels extending
outward from the neurosensory retina, with evident or occult
anastomosis with the choroidal circulation.32 However, the
identification of RAP can be difficult as FA commonly de-
tects occult or minimally classic CNV,33 often associated
with intraretinal accumulation of fluorescein in a petaloid
pattern.34 IPCV was first described by Yannuzzi et al.35 as
polypoidal, subretinal, vascular lesions associated with serous
and hemorrhagic detachments of the retinal pigment epithe-
lium (RPE). FA is not as useful in imaging IPCV as it is in
types 1 and 2 or even type 3 neovascularization, since most
patients with IPCV have fundus hyperpigmentation or ser-
osanguineous complications that may obscure the character-
istics of the polypoidal choroidal vascular abnormalities.36
Another finding in nAMD patients is the pigment epi-
thelium detachment (PED), which represents the separation
of the RPE from the underlying Bruch’s membrane. It can
be classified as serous PED (sPED) or fibrovascular PED
(fPED). On FA, sPED shows a rapid, bright, and uniform
filling of the entire lesion, reaching a peak in very late
frames without leakage. sPED has sharply delineated mar-
gins, caused by the tight adherence of RPE to the Bruch’s
membrane. sPED could be avascular, if it is associated with
disruption of the hydrophobic barrier between RPE and
choriocapillaris,37 or it could be associated with occult CNV
(appearing as a notching at the border of PED).38 sPED is
also a prominent feature of subtypes of nAMD such as IPCV
and RAP lesions.37
fPED is a subset of occult CNV and is defined as an area
of irregular elevation corresponding to granular hyper-
fluorescence, which emerges within 1 to 2min from fluo-
rescein injection, with persistent staining or leakage in late
frames.39 The management of patients with PED secondary
to neovascular AMD is controversial and no consensus
treatment guidelines are yet available. Traditionally,
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clinicians did not consider PED in the decision algorithms
for retreatment, and none of the large-scale, prospective
trials have included PED in their retreatment criteria. The
VA after anti-VEGF therapy may not depend on the re-
sponse of PED, but seems to be influenced by the response
of other exudative findings, such as fibrin, hemorrhage,
subretinal fluid (SRF), and intraretinal fluid (IRF).40
The accumulation of serous fluid beneath or within the
neurosensory retina is considered a biomarker of disease
activity and appears on angiograms as dye leakage or dye
pooling in a petaloid pattern. As CNV growth is associated
with deep structural changes involving choriocapillaris,
RPE, and neurosensory retina, distinguishing leakage from
fluorescein staining on FA can be challenging, especially
after several treatments.41,42 CNV may not exhibit fluores-
cein leakage if it has undergone involution (spontaneous or
induced by anti-VEGF therapy) or it is enveloped by RPE
proliferation.32
Indocyanine green angiography
ICGA allows the direct visualization of both classic and
occult CNV. Moreover, it is employed to identify and dif-
ferentiate specific subtypes of choroidal neovascular lesions,
as the higher binding affinity of indocyanine green to plasma
proteins leads to a slower rate of leakage from the chor-
iocapillaris compared to fluorescein.43
ICGA is very helpful in imaging RAP branching, showing
anastomotic retinal vascular communications between retina
and choroid. Another ICGAfinding is the late-phase staining of
fibrin, which may be present in the cystic spaces.44 According
to some authors, RAP can be classified into three stages: in-
traretinal neovascularization (stage 1), subretinal neovascu-
larization with retinal anastomosis (stage 2), and CNV with
retinal-choroidal anastomosis (stage 3).44 The progression
from one stage of the disease to another is considered an im-
portant sign of activity, and, indeed, stage 3 RAP is associated
with outer retina destruction and RPE detachment.45–47
IPCV primarily involves the inner choroidal vasculature
and, therefore, it is better visualized using ICGA.48 ICGA
should be performed to diagnose IPCV when routine ophthal-
moscopic examination indicates a serosanguineous SRF,
spontaneous massive subretinal hemorrhage, notched or hem-
orrhagic PED, and poor response to anti-VEGF therapy.49
There are some ICGA characteristics, peculiar to poly-
poidal lesions that need to be investigated to clarify whether
the lesion is active and, thus, requires treatment. In the late
phase of ICGA, the lesion core may become hypofluorescent
because of the washout of the dye, producing a ring-like
staining of polyps. This may help to distinguish between
polyps that are actively leaking (visible as a ring of hyper-
fluorescence) and those that are not (hypofluorescent ring).50
The total lesion size for IPCV is the area comprising all
polyps and their branching vascular network (BVN) as
shown by ICGA. Frequently, it is possible to observe pul-
satile filling of the polyp in dynamic ICGA as a sign of
IPCV (level 3 evidence).51
The initial goal of treatment of active IPCV is the re-
gression of polyps as observed by ICGA: all IPCV lesions
(polyps plus BVN) need to be treated as indicated by ICGA
for treatment-naive patients.51,52 Incomplete regression of
polyps following initial anti-VEGF treatment is not un-
common and can be assessed by ICGA at the 3-month visit.
Contrary to FA, sPED appears as a hypofluorescent lesion
during all phases of ICGA. Moreover, ICGA allows to vi-
sualize the presence of an associated CNV and characterize
the precise subtype (occult CNV, RAP, or IPCV). ICGA
also provides a more accurate definition of fPED, allowing a
better appreciation of its precise nature.39
Optical coherence tomography
The expanding use of anti-VEGF agents has led to a sig-
nificant increase in the number of follow-up control visits and
OCT, a quick and noninvasive diagnostic technique, has be-
come the method of first choice in daily clinical practice. The
neovascular AMDfindings recognizablewith spectral domain-
OCT (SD-OCT) may be classified based on their reflectivity.
SRF and IRF are generally hyporeflective, but other findings
associated with choroidal new vessels, including hemorrhage,
lipid exudates, pigment clumping, subretinal fibrosis, and
CNV itself demonstrate hyperreflectivity.53
SRF and IRF are considered signs of CNV activity in both
naive and treated patients. SRF is defined as an elevation of
the neurosensory retina and, on OCT, it appears as an area of
low reflectivity between the outer surface of the retina and the
RPE.54,55 SRF is associated with all lesion types and is typ-
ically the first exudative sign in type 1 lesions. IRF may
determine diffuse retinal thickening or cystoid space forma-
tion.41 Intraretinal cystoid fluid is a sign of a more aggressive
lesion type and late presentation of chronic occult CNV.
Massive IRF exudation is often associated with lipid ex-
udates. They are commonly seen in the outer retina, but may
be scattered throughout all retinal layers and, in some cases,
may cluster to form confluent plaques, particularly in pa-
tients with RAP.56
Hyporeflectivity above the RPE or between retinal layers
does not necessarily mean lesion activity, as some hypore-
flective lesions visible on OCT scans are not associated with
fluorescein leakage. A recent OCT finding called ‘‘wedge-
shaped subretinal hyporeflective lesions’’ should be distin-
guished from SRF, as its presence does not require retreat-
ment.57 This lesion is typically located in areas of geographic
atrophy in AMD eyes. Moreover, the retina overlying these
hyporeflective lesions is characterized by the absence of an
outer nuclear layer (ONL), the external limiting membrane,
the ellipsoid zone, the interdigitation zone, and the RPE.57
Similarly, not all IRF on OCT are caused by active CNV,
and it is important to differentiate between cystoid fluid
caused by exudative CNV (exudative IRC) and that associ-
ated with neurosensory degeneration (degenerative IRC).
Exudative IRCs are relatively large circular or ovoid
spaces, often overlying pigment epithelial detachments
(type 1 or 3 lesions) or neovascular tissue (type 2 CNV).42
Degenerative IRF is characterized by small cystoid spaces,
usually located in the inner nuclear layer of the retina, and is
not associated with angiographic leakage. Moreover, on
OCT, pseudocysts are not associated with retinal thickening,
which differentiates them from exudative IRF.58 Retinal
pseudocysts should be further distinguished from outer
retinal tubulations (ORTs), which can be observed in the
ONL and correspond to degenerating photoreceptors ar-
ranged in a circular or ovoid manner.59
PEDs have traditionally been classified based on clinical
findings, FA and ICGA, but OCT has introduced new
qualitative parameters. According to their different etiology
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(nAMD, IPCV, presumed ocular histoplasmosis, and central
serous chorioretinopathy), three subtypes of PED may be
identified based on the reflectivity of the material under the
RPE: hollow (primarily hyporeflective), solid (primarily
hyperreflective), and mixed (combination of solid and hol-
low PEDs).60 In nAMD patients, hollow PEDs showed the
best response to anti-VEGF, whereas solid PEDs showed the
poorest response.60 This suggests that the likelihood of PED
flattening is inversely related to its reflectivity. Thus, in
nAMD patients, we could consider hollow PEDs as possible
signs of lesion activity, as they could have a good response
to other intravitreal injections.
Optical coherence tomography angiography
OCT-A allows the noninvasive visualization of retinal and
choroidal vascular flow by motion-contrast imaging.61 By this
instrument, the CNV subtypes are defined according to the
position of the vascular decorrelation signal: in type 2, it is
located immediately above the RPE, and in type 1, below the
RPE or between the Bruch’s membrane and the RPE layers.62
A variety of CNV morphologies have been described,
including the ‘‘medusa’’ shape, ‘‘seafan’’ shape, ‘‘glomer-
ular’’ shape, and the ‘‘dead tree’’ appearance.63,64 Yet, the
clinical relevance of these morphologic variations remains
controversial, since they have not yet been definitely cor-
related to CNV activity.65 A study conducted by Coscas
et al.62 found a correlation between some OCT-A features
and CNV needing prompt treatment, including the abun-
dance of branching, the presence of vascular anastomoses
and loops, the presence of a peripheral arcade of the vessel
termini, and the existence of a perilesional hypointense halo.
It has been hypothesized that anti-VEGF treatment may
prune smaller vessels in the neovascular lesion, reducing the
overall lesion size.66 Indeed, some studies focused on a
quantitative analysis of CNV, considering mainly lesion size
and automated flow analysis to obtain data regarding lesion
activity.67,68 However, the measurement reproducibility is
challenging and image analysis algorithms have not been
adequately validated.65
The ability to perform depth-resolved analysis to deter-
mine the level of the lesion could be a significant advantage
of OCT-A in characterizing RAP lesions, although experi-
ence with OCT-A in RAP is still limited.69 Regarding the
lesion activity assessment, a recent study evaluated the re-
sponse of type 3 lesions to anti-VEGF therapy and dem-
onstrated a decrease in lesion size.70
The motion rate of scattering particles, such as erythrocytes,
in IPCV lesions depends on the polyp size: OCT-A is more
suitable to detect larger polyps in which blood speed is higher,
whereas small polyps may not be identified. Moreover, the
faster flow velocity at the periphery of large polypoidal lesions
makes them appear as rings. On the other hand, OCT-A seems
highly effective in tracing the BVN of IPCV.71,72
No studies are available regarding the OCT-A features of
treated polypoidal lesions. Still, it has been hypothesized
that, in treated patients, shrinkage of the polyps could
hamper their identification.72
Discussion
Patients undergoing intravitreal injections are followed
up according to their treatment schedule. The morphologic
response of neovascular lesions to anti-VEGF therapy may
be monitored with all the aforementioned imaging tech-
niques, even though the information regarding the lesion
activity obtained with different tools may be contrasting or
disputable.
We performed a comparative analysis of the imaging
techniques to develop a treatment algorithm. One possible
limitation of our study might come from the lack of geo-
graphic diversity of the board. However, we believe that the
scientific background and the specific clinical exposure of
each member of the panel guarantee comprehensive view-
points to meet the aims of the study.
Color fundus photography
CFP was the basis of studies performed before the advent
of more recent imaging instruments. Indeed, the continued
use of CFP in current clinical trials allows the comparison
with data from past studies. Mokwa et al.73 reported that,
compared to FA and SD-OCT, CFP had a lower sensitivity
in detecting CNV activity. However, the appearance of new
retinal or subretinal hemorrhages, representing active le-
sions, may not be detectable on OCT.27
FA and ICGA
Traditionally, FA has been considered the reference
standard to detect nAMD activity. Yet, this is particularly
challenging after anti-VEGF/photodynamic therapy, as su-
perimposed hypo/hyperfluorescence due to scarring or
atrophic changes can mask dye leakage. ICGA may inte-
grate FA findings, especially for RAP. Indeed, FA is useful
to identify early-stage RAP, but, in advanced stages, fluo-
rescein stains the whole vascular network and exudative
process, resulting in an occult-like pattern.
ICGA is able to delineate abnormal vessel structure and
determine the nature of the indistinct hyperfluorescence seen
on FA.30 Morphologic response to treatment of IPCV le-
sions is usually best appreciated with ICGA, but, sometimes,
the complete regression of polyps detected by ICGA is as-
sociated with persistant leakage on FA and clinical or OCT
signs of activity.48,51
Optical coherence tomography
First employed in the 1990s, OCT is the most frequently
used tool in the daily practice management of nAMD. The
recent European Society of Retina Specialists (EURETINA)
guidelines recommend to monitor disease activity monthly
using SD-OCT.14
IRF or SRF may be present despite regular treatment. In
the PrONTO study, 2/40 eyes (5%) receiving a PRN regi-
men needed monthly retreatment, whereas results of the
CATT trial showed fluid persistence (including sub-RPE
fluid) at the 12-month visit in 53% of patients assigned to
the monthly treatment arm.16,74
The central retinal thickness (CRT) increase has been
widely used as a retreatment criterion in many clinical trials.
However, a recent review showed the poor reproducibility
of CRT values due to segmentation errors, poor fixation, and
use of different OCT devices. Moreover, CRT includes a
medley of different retinal compartments and, therefore, is
not able to distinguish variations at the level of individual
pathological components.41
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Although conventional doses of anti-VEGF agents may
reduce the associated hemorrhage, IRF, or SRF, vascular-
ized PED (vPED) does not typically resolve.75 The reasons
for the poor response of vPED to anti-VEGF therapy remain
unknown. A recent study by Inoue et al.76 evaluating the
prognosis of nAMD patients after intravitreal anti-VEGF
therapy according to the PED subtype, showed better results
in subjects with sPED. The management of patients with
PED secondary to AMD is controversial and no consensus
treatment guidelines are currently available as previously
reported.40 However, quantitation of the change in retinal
PED volume and area with SD-OCT may be useful to de-
termine when to retreat AMD patients.77
FA still plays a key role in the initial diagnostic process,
since OCT and FA examine different aspects of IRF dy-
namics. OCT focuses on static anatomical features (retinal
thickening and the presence of SRF and IRF), while FA
addresses more dynamic aspects of fluid leakage and, as
a result, their findings do not always agree. Scan rates
and resolution parameters of OCT have improved over the
past decade and continue to develop. If OCT could accu-
rately detect reactivation of nAMD, then FA would not be
necessary.78
A number of studies have examined the relationship
between OCT findings and fluorescein patterns in nAMD.
In these studies, classic CNVs are associated with signifi-
cantly greater volumes of subretinal hyperreflective mate-
rial than occult CNVs, which are more commonly
associated with PED.56
On OCT, active RAP lesions are typified by frank cystoid
macular edema overlying an fPED and associated with
SRF.56 SD-OCT could provide more accurate information
on the location of the lesion, identifying areas of intraretinal
neovascularization and activity of the disease (PED, IRF).79
Although ICGA is essential in the initial diagnostic pro-
cess, the follow-up of RAP lesions could be effectively
performed with OCT. IRF or SRF accumulation is, by itself,
sufficient to define the lesion as active. Coscas et al. re-
ported that eyes with a baseline PED showed a lower mean
improvement in VA, but there is no consensus on whether
PED in the absence of IRF or SRF or leakage on FA should
be considered a sign of lesion activity.80
IPCV may be considered active if there is clinical, OCT,
or FA/ICGA evidence of any of the following features at-
tributable to IPCV: SRF or IRF, PED, subretinal or sub-RPE
hemorrhage, or fluorescein leakage.51
OCT could be more suitable to detect IPCV by recog-
nizing abnormalities that surround the polypoidal lesions.
Moreover, PED on the OCT often correspond to polypoidal
lesions detected by ICGA.81 Furthermore, it is possible to
identify polypoidal structures beneath RPE and attached at
the back surface of RPE by high-resolution OCT scans.36
The diagnostic precision of these imaging techniques has
been compared in a number of studies (Table 2)78,82–94: on
average, OCT shows a high sensitivity (up to 100%) in
detecting lesion activity although specificity seems low.
Optical coherence tomography angiography
OCT-A has been conceived as a dye-free alternative to
conventional angiography. It offers a static image of the
vasculature, allowing a sharp visualization of microvascular
details that are usually obscured by dye leakage or pooling
on FA or ICGA. However, compared with standard angi-
ography, the usefulness of OCT-A seems still limited by its
small field of view (3 · 3mm or 6 · 6mm) and by the high
chance of artifacts, including segmentation errors, signal
blockage, motion artifacts, and projection artifacts.65
Table 2. Overview of Data on the Agreement Between Optical Coherence Tomography and Angiography
Study
Eyes/
patients (n) CNV status OCT
Agreement FA-OCT
based on
Sensitivity
(%)
Specificity
(%)
Salinas-Alama´n et al.82 62 eyes Naive PDT-t TD SRF, IRF 97 n.a.
TD SRF, IRF 96 59
Sandhu and Talks83 131 eyes Naı¨ve TD CNV, SRF, IRF, PED 96 66
Eter and Spaide84 60 eyes PDT-t TD SRF, IRF 80 80
Van de Moere et al.85 121 eyes PDT-t TD SRF 41 83
IRF 83 53
Gross CMO 23 96
Solitary foveal cyst 13 75
CRT 63 82
van Velthoven et al.86 30 pts PDT-t TD CMO, SRF, CRT 65 43
Talks et al.87 134 pts Naive TD Findings of nAMD 100 65
Malamos et al.88 37 pts Naive SD CNV, SRF, IRF, PED, CRT n.a. n.a.
Henschel et al.89 14 pts PDT-t TD SRF 71 70
IRF 90 40
SRF, IRF 97 37
Khurana et al.90 59 eyes IV-t TD SRF, IRF 59 63
SD SRF, IRF 90 47
Giani et al.91 93 pts Naı¨ve SD SRF 68 88
SRF, IRF, PED 94 27
Padnick-Silver et al.92 79 pts Naı¨ve TD SRF, IRF, PED 80 93
Do et al.93 87 pts Naive TD SRF, IRF, CRT 69 57
Wilde et al.94 411 pts Naive SD SRF, IRF, PED 100 80
Castillo et al.78 400 pts Mixed TD/SD Meta analysis 85 48
CMO, cystoid macular edema; CRT, central retinal thickness; IV-t, IV treated; n.a., not applicable; nAMD, neovascular AMD; PED,
pigment epithelium detachment; PDT-t, PDT-treated; pts, patients.
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Compared to FA, OCT-A has been reported to be reliable
in detecting CNV: the sensitivity and specificity of OCT-A
were reported to be 50% and 91%, respectively, in one
study95 and 86.5% and 67.6%, respectively, in another one96
ICGA is especially useful to detect polypoidal lesions.
Compared to ICGA, OCT-A has been shown to be able to
more clearly visualize BVNs associated with IPCV. Still,
OCT-A is not able to detect polyps with the same accuracy
of ICGA, as, in small lesions, the blood speed is too low to
generate a detectable decorrelation signal.71,72,97
Some investigators have proposed OCT-A as a suitable
alternative to FA. Yet, the vascular patterns described on
OCT-A have not yet been correlated with lesion activity,65
and there are no specific OCT-A imaging biomarkers that
seem to correlate with the degree of leakage visible on
conventional FA.98
OCT-A is almost an upgraded OCT and appears able to
integrate the structural data achievable by OCT. Indeed,
Inoue et al.98 found that OCT-A, coupled with structural
OCT, attained a better detection of type 1 CNV compared to
FA alone or OCT-A alone.
OCT-Amay potentially translate into a reduced need for FA
in clinical settings; nevertheless, OCT-A seems to be neces-
sarily complementary to structural OCT, as a clinical endpoint
indicating CNV quiescence has not been identified.65
Moreover, there are several patient- and disease-related
factors that are known to preclude the reliable visualization
of NV using OCT-A, and the utility of OCT-A for managing
NV remains unclear.64
Consensus Statement
After considering all the available evidence, the panel
unanimously agreed upon an OCT-based algorithm to detect
lesion activity in patients with nAMD and schedule re-
treatment strategies with intravitreal anti-VEGF (Fig. 1). A
100% agreement was made possible because each contro-
versial point (eg, role of PED and usefulness of CFP alone)
was discussed thoroughly based on objective data reported
in the published literature.
Conclusions
Although predicting the clinical response of an eye to
anti-VEGF therapy is not possible yet, it has been demon-
strated that, for each patient, the duration of the anti-VEGF
effect after every injection appeared quite stable over up to 3
years.99 Therefore, the precise quantification of each pa-
tient’s personal disease-free interval, strictly dependent from
a prompt recognition of persistence/recurrence of CNV ac-
tivity, is a fundamental requirement for the success of the
PRN, T&E, and O&P protocols.16–20
An OCT-based algorithm appears the quickest and most
effective way to guide the decision of the treatment sched-
ule, since OCT (1) is able to identify the lesion activity
about 20 days before VA becomes affected,22 (2) shows a
high agreement with angiographic findings (Table 2), and
(3) allows a quantitative analysis of CNV features.
The diagnostic process must include fundus examination,
as the appearance of a new hemorrhage could be in itself
sufficient to demonstrate CNV reactivation14 and may not
always be detectable on OCT.27 The LUCAS and SEVEN-
UP trials reported that, at baseline, about a quarter of the
study population presented with retinal hemorrhages.20,100
Although no data are available regarding the rate of new
hemorrhages during follow-up, it is reasonable to hypothe-
size that retinal bleeding might be present in a small, but
significant number of active lesions.
Despite confounding features, SRF normally indicates le-
sion activity and may be easily detected by OCT. However, if
SRF does not decrease after further injections, it should be
considered the consequence of chronic RPE decompensation
FIG. 1. Flow chart for clinical follow-up
based on morphological features of CNV in
patients undergoing treatment for neovas-
cular age-related macular degeneration.
CNV, choroidal neovascularization; IRF,
intraretinal fluid; OCT, optical coherence
tomography; RPE, retinal pigment epitheli-
um; sPED, serous pigment epithelium de-
tachment; SRF, subretinal fluid.
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or a degenerative phenomenon.57 IRF, defined as the presence
of intraretinal cysts, nearly always indicates active lesions,
with a few exceptions, including degenerative cysts associ-
ated with subretinal fibrosis and ORT.41
Even if the presence of a PED is not traditionally con-
sidered a retreatment criterion, a new onset or an increase in
sub-RPE fluid should be introduced in the decision algo-
rithm. Indeed, there have been reports that hollow/serous
PEDs respond to anti-VEGF, confirming that it is a probable
sign of lesion activity.60 Moreover, enlargement of the PED
area or volume might serve as a predictor of CNV re-
activation, before IRF or SRF appearance.40
During the last decade, OCT has progressively become the
reference method in follow-up visits, as it is faster and con-
sidered to be sufficiently reliable.101 Our study group con-
firmed this clinical practice as strongly supported by literature
evidence, and developed a treatment algorithm based on OCT
findings, with the exception of clear biomicroscopic findings.
Future development of the OCT-A technology will probably
improve the precision of this method, to make real-world
outcomes much closer to trials’ results.
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